Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Piramal Pharma, demerged from Piramal Enterprises in 2022, operates three businesses: a global CDMO (Piramal Pharma Solutions) with development and manufacturing sites across India, the US and UK; complex hospital generics (inhalation anaesthetics like sevoflurane, injectables) sold globally; and an India consumer healthcare portfolio with brands such as Lacto Calamine, Littles and i-pill. CDMO is the largest revenue segment.
It is among the larger India-headquartered CDMO players with a significant US/EU manufacturing footprint.
Piramal Pharma Ltd. is a constituent of NIFTY 500, NIFTY HEALTHCARE, NIFTY PHARMA, NIFTY SMALLCAP 100, NIFTY SMALLCAP 250, NIFTY SMALLCAP 50. See where it sits on the market heatmap →
Consolidated annual figures taken from Piramal Pharma Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | -2.46 | 0.69 | 0.14 |
| Book value / share (₹) | 61.50 | 61.35 | 59.80 |
| Return on equity | -4.0% | 1.1% | 0.2% |
| Return on capital employed | 0.7% | 5.3% | 4.2% |
| Operating margin | 1.0% | 6.9% | 5.6% |
| Net margin | -3.7% | 1.0% | 0.2% |
| EBITDA | ₹922 Cr | ₹1,445 Cr | ₹1,196 Cr |
| Free cash flow | ₹763 Cr | ₹228 Cr | ₹293 Cr |
| Total debt | ₹5,495 Cr | ₹4,720 Cr | ₹4,559 Cr |
| Debt to equity | 0.67 | 0.58 | 0.58 |
| Interest coverage | 0.3 | 1.5 | 1.0 |
| Current ratio | 1.51 | 1.54 | 1.25 |
| Shares outstanding | 1,32,71,60,000 | 1,32,43,50,000 | 1,32,29,50,000 |
Open the full income statement, balance sheet and cash flow for PPLPHARMA →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.